Entering text into the input field will update the search result below

AV Therapeutics, Inc. (AVTH) Commences Trading On The OTCQB

Jan. 03, 2014 1:49 PM ETAVTH
MissionIR profile picture
MissionIR's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Small cap

Seeking Alpha Analyst Since 2010

We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to building shareholder value. View our website at www.MissionIR.com MissionIR provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.missionir.com.

Cancer therapeutics and vaccines developer AV Therapeutics announced that on Dec. 27, its common stock began trading on the OTC Market Group's OTCQB Marketplace under the symbol "AVTH."

The company has identified and patented Capridine, a chemo therapeutic drug that has demonstrated specific activity against prostate and colon cancer in preclinical models. Capridine is anticipated to be AV Therapeutics' frontline product - specifically in prostate cancer, for which limited chemotherapy treatments currently exist. Counting funding from the National Institutes of Health and the Department of Defense, more than $6 million has been invested in the development of the drug.

AV Therapeutics plans to enter Phase I trials for Capridine in the second quarter of 2014. These trials will be led by the Prostate Consortium, which is comprised of 16 leading academic medical centers in the United States.

AV Therapeutics is focused on the business of developing cancer therapeutics and immunotherapeutic vaccines that can be used alone or combined with prevalent treatment modalities like chemotherapy and radiation to treat active disease and prevent metastases and recurrence. The company's immune-therapeutics is based on the capability of certain proprietary reagents to re-educate or reprogram an immune system to target micro-metastases that were previously unidentified. AV Therapeutics plans to clinically develop both approaches for metastatic and early-stage prostate cancer.

For more information, visit the company's website at avtherapeutics.com

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.